AdvaMed-Chair Exit Interview: Vince Forlenza On Medtech Policy Priorities

BD CEO Vince Forlenza just finished his two-year term as board chairman of AdvaMed. For the most part, his successor will face the same priorities he did during his tenure: repealing the 2.3 percent medical device excise tax and reauthorizing device user fees. Forlenza spoke with Medtech Insight in this podcast interview.

Vince Forlenza

Vince Forlenza, president and CEO of Becton Dickinson & Co., just finished his two-year term as chairman of AdvaMed's board. This month, he handed over the reins to Nadim Yared, CEO of CVRx Inc. (Also see "Q&A With Nadim Yared: AdvaMed's Next Chair On Capital Formation And Global Challenges" - Medtech Insight, 4 August, 2016.)

In an exit- interview podcast with Medtech Insight, Forlenza discussed the experience, his advice for Yared and AdvaMed's approach to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.

MDUFA VI Talks Begin with Familiar Priorities: Innovation, Transparency, Safety

 
• By 

At an Aug. 4 public meeting on MDUFA VI, FDA officials, industry representatives, and patient advocates outlined their priorities for the next user fee agreement, highlighting goals such as improved transparency, streamlined reviews, enhanced safety measures, and greater patient involvement.

Bipartisan Senate Bill Would Give Patients ‘True Price Tag’ Prior To Care

 

Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

More from Policy & Regulation

Cardiology And PTA Procedures In Germany’s Expanded Hybrid DRGs List 2026

 
• By 

2026 reimbursement calculations for the list of hybrid DRGs – a mechanism to incentivize day cases over inpatient surgery – will be issued in few weeks’ time. The medtech industry has made its demands known.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By 

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Warning Letters - July 2025

The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.